Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.
Journal: Cancer discovery
Published: July 12, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Journal: Journal for immunotherapy of cancer
Published: March 11, 2024
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Journal: Journal for immunotherapy of cancer
Published: July 15, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 20, 2022
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Journal: Journal for immunotherapy of cancer
Published: January 14, 2022
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Journal: Investigational new drugs
Published: November 19, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 10, 2020
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Journal: Cancer
Published: November 30, 2018
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
Journal: British journal of cancer
Published: October 12, 2017
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 27, 2016
A urologic perspective on management of localized and metastatic RCC.
Journal: Oncology (Williston Park, N.Y.)
Published: August 09, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026